FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate

Key Takeaways FDA grants Breakthrough Therapy tag to LLY's sofetabart mipitecan for certain ovarian cancer patients.Phase III FRAmework-01 study is testing LLY's candidate alone in platinum-resistant ovarian cancer.LLY says early results across all expression levels are promising and could support a new treatment option.Eli Lilly and Company (LLY) announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor alpha (FRα) antibody-drug conjugate (ADC), sofetabart mipitecan ...